339 related articles for article (PubMed ID: 27966034)
1. Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function.
Usman M; Frey OR; Hempel G
Eur J Clin Pharmacol; 2017 Mar; 73(3):333-342. PubMed ID: 27966034
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
Pai MP; Cojutti P; Pea F
Clin Pharmacokinet; 2015 Sep; 54(9):933-41. PubMed ID: 25850987
[TBL] [Abstract][Full Text] [Related]
3. Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations.
Ramon-Lopez A; Allen JM; Thomson AH; Dheansa BS; James SE; Hanlon GW; Stewart B; Davies JG
J Antimicrob Chemother; 2015 Mar; 70(3):882-90. PubMed ID: 25362574
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients.
Kees MG; Minichmayr IK; Moritz S; Beck S; Wicha SG; Kees F; Kloft C; Steinke T
J Clin Pharmacol; 2016 Mar; 56(3):307-15. PubMed ID: 26222202
[TBL] [Abstract][Full Text] [Related]
5. Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases.
Isla A; Canut A; Arribas J; Asín-Prieto E; Rodríguez-Gascón A
Eur J Clin Microbiol Infect Dis; 2016 Mar; 35(3):511-9. PubMed ID: 26782093
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
[TBL] [Abstract][Full Text] [Related]
7. A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients.
Mathew SK; Mathew BS; Neely MN; Naik GS; Prabha R; Jacob GG; K S; Fleming DH
Ther Drug Monit; 2016 Oct; 38(5):593-9. PubMed ID: 27454665
[TBL] [Abstract][Full Text] [Related]
8. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation.
Dong J; Xiong W; Chen Y; Zhao Y; Lu Y; Zhao D; Li W; Liu Y; Chen X
Int J Antimicrob Agents; 2016 Mar; 47(3):202-9. PubMed ID: 26895604
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.
Cojutti P; Sartor A; Righi E; Scarparo C; Bassetti M; Pea F
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760900
[TBL] [Abstract][Full Text] [Related]
10. Population Pharmacokinetic Analysis of Meropenem After Intravenous Infusion in Korean Patients With Acute Infections.
Kim YK; Lee DH; Jeon J; Jang HJ; Kim HK; Jin K; Lim SN; Lee SS; Park BS; Kim YW; Shin JG; Kiem S
Clin Ther; 2018 Aug; 40(8):1384-1395. PubMed ID: 30093133
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic–pharmacodynamic target attainment analysis of meropenem in Japanese adult patients.
Ikawa K; Morikawa N; Ohge H; Ikeda K; Sueda T; Taniwaki M; Kurisu K
J Infect Chemother; 2010 Feb; 16(1):25-32. PubMed ID: 20082106
[TBL] [Abstract][Full Text] [Related]
12. Short versus long infusion of meropenem in very-low-birth-weight neonates.
Padari H; Metsvaht T; Kõrgvee LT; Germovsek E; Ilmoja ML; Kipper K; Herodes K; Standing JF; Oselin K; Lutsar I
Antimicrob Agents Chemother; 2012 Sep; 56(9):4760-4. PubMed ID: 22733063
[TBL] [Abstract][Full Text] [Related]
13. Optimization of meropenem dosage in the critically ill population based on renal function.
Crandon JL; Ariano RE; Zelenitsky SA; Nicasio AM; Kuti JL; Nicolau DP
Intensive Care Med; 2011 Apr; 37(4):632-8. PubMed ID: 21136037
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.
Isla A; Rodríguez-Gascón A; Trocóniz IF; Bueno L; Solinís MA; Maynar J; Sánchez-Izquierdo JA; Pedraz JL
Clin Pharmacokinet; 2008; 47(3):173-80. PubMed ID: 18307371
[TBL] [Abstract][Full Text] [Related]
15. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
Burger R; Guidi M; Calpini V; Lamoth F; Decosterd L; Robatel C; Buclin T; Csajka C; Marchetti O
J Antimicrob Chemother; 2018 Dec; 73(12):3413-3422. PubMed ID: 30304491
[TBL] [Abstract][Full Text] [Related]
16. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.
Roberts JA; Kirkpatrick CM; Roberts MS; Robertson TA; Dalley AJ; Lipman J
J Antimicrob Chemother; 2009 Jul; 64(1):142-50. PubMed ID: 19398460
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation.
Kong L; Tang Y; Zhang X; Lu G; Yu M; Shi Q; Wu X
Ann Pharmacother; 2017 Nov; 51(11):970-975. PubMed ID: 28677407
[TBL] [Abstract][Full Text] [Related]
18. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.
Ulldemolins M; Soy D; Llaurado-Serra M; Vaquer S; Castro P; Rodríguez AH; Pontes C; Calvo G; Torres A; Martín-Loeches I
Antimicrob Agents Chemother; 2015 Sep; 59(9):5520-8. PubMed ID: 26124172
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patients.
Cojutti P; Maximova N; Pea F
Antimicrob Agents Chemother; 2015 Sep; 59(9):5535-41. PubMed ID: 26124157
[TBL] [Abstract][Full Text] [Related]
20. Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit.
Cheatham SC; Fleming MR; Healy DP; Chung EK; Shea KM; Humphrey ML; Kays MB
J Clin Pharmacol; 2014 Mar; 54(3):324-30. PubMed ID: 24122855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
